Innovation  by DeMaria, Anthony N.
Journal of the American College of Cardiology Vol. 62, No. 3, 2013
 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.06.002EDITOR’S PAGEInnovationAnthony N. DeMaria,
MD, MACC
Editor-in-Chief,
Journal of the American
College of Cardiology
.it is the
recognition of an
unmet need
accompanied by the
vision of a possible
solution, that is
then developed to
the point of clinical
application, that
captures our
imagination and
respect.Innovation is the driving force that produces advances in medicine in general, andcardiology in particular. I have just returned from the British Cardiac Society meetingwhere I served as chair of a fascinating session on medical innovation. The speakers
included Mandy Haberman, a woman who invented the nonspill baby cup, and Andrew
Cleeland, who administered the development of renal artery denervation for hypertension.
I was especially lucky to hear a magniﬁcent presentation by Dr. Alain Cribier who, as the
Paul Wood lecturer, discussed the process of innovation in the context of his development of
transcatheter aortic valve replacement (TAVR or TAVI, take your pick). In aggregate these
lectures highlighted the challenges and requirements inherent to bringing a novel idea from
conception to a ﬁnished product with clinical application of value to society.
All speakers stressed the fact that successful innovation had to begin with the identiﬁcation
of an unmet need. This concept seems pretty obvious, since all of us are regularly confronted by
problems that lack solutions. However, at least for me, the tendency has just been to accept
that there is no solution for some conditions, and attempt to deal with the dilemma as best
as possible. Very often innovation is the results of a chance observation. In fact, the one
procedure that I had a role in discovering with Bill Bommer, that is myocardial contrast echo,
was the result of wondering what would happen if microbubbles were injected into the
coronary arteries. It was only after seeing the myocardium opacify that we recognized that this
might be a useful technique to assess myocardial perfusion and coronary blood ﬂow. So, simple
as it sounds, there is a deﬁnite skill in identifying an unmet need and conceptualizing an
answer. Fortunately for us, serendipity often compensates for the lack of forethought.
Once an unmet need is recognized and a plausible solution is identiﬁed, a successful
innovator has to be a risk taker and be willing to fail. This may be the most difﬁcult aspect of
the process for most of us. Physicians have generally been extremely successful in life, and the
concept of risking almost everything on an unproven idea with a signiﬁcant likelihood of
failure is not readily accepted. In fact, it is often said that one of the major limitations of
funding agencies, such as the National Heart, Lung, and Blood Institute, is that they seek
assurances that proposed projects will be successful before support is provided. Consider-
ation of clinically important procedures done on a daily basis that were developed without
signiﬁcant National Institutes of Health support, such as echocardiography, coronary bypass
surgery, angioplasty/stents, and pharmaceuticals, such as beta-blockers, lends credence to
this concept. The potential for failure is inherent in innovation, and can provide a signiﬁcant
barrier to success.
Dr. Cribier and the other speakers also emphasized the need for true innovators to be
passionate and driven to achieve their goal. Novel ideas rarely lead to straightforward
implementation. Rather, there are usually obstacles along the way, each of which must be
overcome. The innovator must be relentless in pursuit of the solution. This is especially true
in regard to the skepticism that is typically encountered early in the process. All of the
speakers indicated that they were told in the initial stages that their ideas would never work,
or if they could be implemented would have been done such a long time ago. So overcoming
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254obstacles in the face of skepticism that the new idea could
be successful requires a unique personality, and one that
characterizes the true innovator.
Having identiﬁed an unmet need and conceived
a solution, the innovator has to obtain the necessary ﬁnancial
and other support to carry out the development. This
requires convincing individuals who have resources to devote
them to a project with an inherent risk of failure, which is
not an easy task. Each of the speakers related the number of
times they were turned down for support before a willing
source was identiﬁed. Additional steps also involve obtaining
patents and other legal issues. Medical education almost
never provides physicians with the knowledge of how this is
done or the skill set to do it successfully. Some institutions,
such as UCSD and Emory, have begun to develop trans-
lational research training programs that include ﬁnancial and
regulatory aspects of innovation in addition to the scientiﬁc
aspect. Whether and when in the training process this
should be done, if at all, received varying opinions from the
speakers. Nevertheless, it is clear that innovation requires not
only discovery, but also marketing.
Once the innovation is shown to be feasible, the process
now turns to how to deal with enhancements and
competition. While skepticism abounds in the early stages,
after a novel idea has been shown to be possible individuals
often come forth with proposed improvements or even
competing inventions. While incorporation of improve-
ments is clearly part of the innovative process, mere copies
of the new discovery can potentially deny credit and reward
to the innovator and also blunt the incentive for future
breakthroughs. Given the ﬁnancial, legal, and regulatory
issues that must be dealt with in implementing a novel idea,
and the lack of education of physicians in these matters, it
is often critically important to assemble a team that can
properly bring the innovation to the clinical setting.
A number of other issues arose during this interesting
session. The role of the inventor in the testing of the inno-
vation regarding conﬂict of interest was questioned, as was
the importance of ﬁnancial reward. The requirement forinventors to be uninvolved in the clinical testing of their ideas
seems to be especially stringent in medicine. Dr. Cribier, for
his part, told me that his major interest was in seeing the
TAVR procedure developed and implemented, and that he
relinquished ﬁnancial rights early in the process. However,
Andrew Cleeland extolled the fact that the successful sale of
renal denervation had appropriately rewarded not only the
innovators, but also many other individuals who took the risk
of casting their future with an unproven technology and
contributed signiﬁcantly to its ultimate success. There are
obviously a number of ways to view these issues.
The process of innovation is at once daunting and
exhilarating. Serendipity often leads to critically important
advances in medicine, witness penicillin. However, it is the
recognition of an unmet need accompanied by the vision of
a possible solution, that is then developed to the point of
clinical application, that captures our imagination and
respect. I believe that innovation requires a special mindset
and character, one that is visionary, passionate, relentless,
risk taking, and willing to fail. Dr. Cribier told me that he
held multiple patents (I believe that he said nine), but that
along the way he had also experienced failure with a several
of his novel ideas. The entire innovative process will
frequently require a team of individuals with similar char-
acteristics. I think that greater training in translational skills
would enable physicians to participate more fully in the
innovative process, but that discoveries will likely continue to
emanate from a small group of unique individuals. When the
history of medicine is written, it will almost certainly be the
activities and achievements of these true innovators that
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